biotech
biotech Articles
Shares of Flexion Therapeutics dropped early on Wednesday following the announcement of an underwritten public offering.
Published:
Last Updated:
Shares of Biogen slumped early in Tuesday's session following the release of less-than-favorable top-line results from its mid-stage clinical study evaluating opicinumab.
Published:
Last Updated:
Valeant Pharmaceuticals International reported disappointing first-quarter financial results before the markets opened on Tuesday.
Published:
Last Updated:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) has seen more than its fair share of volatility in the market of late. Now shares are surging after it has reached a compromise with the U.S. Food and Drug...
Published:
Last Updated:
inVentiv Group Holdings has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Some call the ASCO annual meeting the "Super Bowl for biotechs" because of the significance it holds for so many companies.
Published:
Last Updated:
Syros Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
The annual meeting for ASCO is generally one of the biggest weeks of the year for the health care sector. However, there are inevitably winners and losers.
Published:
Last Updated:
The analysts at Wedbush focus in on two biotech companies that not only have data that could prove to be huge, but shares of each have been absolutely hammered over the past year,
Published:
Last Updated:
As the annual meeting for the American Society of Clinical Oncology (ASCO) is underway, we are starting to see some winners shake out from it. Currently one of the biggest winners is Vascular...
Published:
Last Updated:
Ocular Therapeutix shares plunged early on Monday following less-than-favorable results, although the news was not all bad.
Published:
Last Updated:
Many speculative calls are made on the biotech stocks. It is here that fortunes can easily be made. The dark side is that these speculative companies quite frequently fail to live up to their hype.
Published:
Last Updated:
A few biotech companies made fantastic runs in Thursday’s session. We have included information about each company, as well as recent trading activity and the consensus price target.
Published:
Last Updated:
A new study from IMS Health has projected that the global market for cancer treatments rose to $107 billion in 2015.
Published:
Last Updated:
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it is looking for.
Published:
Last Updated: